As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Content to be used in accordance with local CPO guidelines
Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First-Line Therapy in Adults With Severe Acquired Aplastic Anemia: Results of the Interventional Phase 2 Single-Arm SOAR Study
Vallejo C
Presentation # 2174 – Poster
December 12, 2021 | 06:00 PM EST
A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination With Dexamethasone as First-line Treatment in Adults Patients With Newly Diagnosed Primary ITP (XPAG-ITP)
Binder M
Presentation # 3151 – Poster
December 13, 2021 | 06:00 PM EST
Treatment of Immune Thrombocytopenia (ITP) With Eltrombopag – Results of the 4th Interim Analysis of the German Non-Interventional Trial RISA
Meyer O
Presentation # 3150 – Poster
December 13, 2021 | 06:00 PM EST
